276 related articles for article (PubMed ID: 32408660)
1. Cell Culture Systems and Drug Targets for Hepatitis A Virus Infection.
Kanda T; Sasaki R; Masuzaki R; Matsumoto N; Ogawa M; Moriyama M
Viruses; 2020 May; 12(5):. PubMed ID: 32408660
[TBL] [Abstract][Full Text] [Related]
2. The JAK2 inhibitor AZD1480 inhibits hepatitis A virus replication in Huh7 cells.
Jiang X; Kanda T; Nakamoto S; Saito K; Nakamura M; Wu S; Haga Y; Sasaki R; Sakamoto N; Shirasawa H; Okamoto H; Yokosuka O
Biochem Biophys Res Commun; 2015 Mar; 458(4):908-12. PubMed ID: 25704089
[TBL] [Abstract][Full Text] [Related]
3. Molecular biology and inhibitors of hepatitis A virus.
Debing Y; Neyts J; Thibaut HJ
Med Res Rev; 2014 Sep; 34(5):895-917. PubMed ID: 23722879
[TBL] [Abstract][Full Text] [Related]
4. Drug Screening for Hepatitis A Virus (HAV): Nicotinamide Inhibits c-Jun Expression and HAV Replication.
Sasaki-Tanaka R; Masuzaki R; Okamoto H; Shibata T; Moriyama M; Kogure H; Kanda T
J Virol; 2023 Feb; 97(2):e0198722. PubMed ID: 36728416
[TBL] [Abstract][Full Text] [Related]
5. Amantadine and Rimantadine Inhibit Hepatitis A Virus Replication through the Induction of Autophagy.
Sasaki-Tanaka R; Shibata T; Moriyama M; Okamoto H; Kogure H; Kanda T
J Virol; 2022 Sep; 96(18):e0064622. PubMed ID: 36040176
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis A: Epidemiology, High-Risk Groups, Prevention and Research on Antiviral Treatment.
Migueres M; Lhomme S; Izopet J
Viruses; 2021 Sep; 13(10):. PubMed ID: 34696330
[TBL] [Abstract][Full Text] [Related]
7. Novel perspectives for hepatitis A virus therapy revealed by comparative analysis of hepatitis C virus and hepatitis A virus RNA replication.
Esser-Nobis K; Harak C; Schult P; Kusov Y; Lohmann V
Hepatology; 2015 Aug; 62(2):397-408. PubMed ID: 25866017
[TBL] [Abstract][Full Text] [Related]
8. Rapid and convenient assays to assess potential inhibitory activity on in vitro hepatitis A replication.
Debing Y; Kaplan GG; Neyts J; Jochmans D
Antiviral Res; 2013 May; 98(2):325-31. PubMed ID: 23528258
[TBL] [Abstract][Full Text] [Related]
9. Sofosbuvir inhibits hepatitis A virus replication in vitro assessed by a cell-based fluorescent reporter system.
Jiang W; Muhammad F; Ma P; Liu X; Long G
Antiviral Res; 2018 Jun; 154():51-57. PubMed ID: 29653132
[TBL] [Abstract][Full Text] [Related]
10. The ZCCHC14/TENT4 complex is required for hepatitis A virus RNA synthesis.
Li Y; Misumi I; Shiota T; Sun L; Lenarcic EM; Kim H; Shirasaki T; Hertel-Wulff A; Tibbs T; Mitchell JE; McKnight KL; Cameron CE; Moorman NJ; McGivern DR; Cullen JM; Whitmire JK; Lemon SM
Proc Natl Acad Sci U S A; 2022 Jul; 119(28):e2204511119. PubMed ID: 35867748
[TBL] [Abstract][Full Text] [Related]
11. Masitinib Inhibits Hepatitis A Virus Replication.
Sasaki-Tanaka R; Shibata T; Moriyama M; Kogure H; Hirai-Yuki A; Okamoto H; Kanda T
Int J Mol Sci; 2023 Jun; 24(11):. PubMed ID: 37298659
[TBL] [Abstract][Full Text] [Related]
12. [Hepatitis A virus infection. A review].
Siegl G
Praxis (Bern 1994); 2003 Oct; 92(40):1659-73. PubMed ID: 14579471
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Potential Anti-Hepatitis A Virus 3C Protease Inhibitors Using Molecular Docking.
Sasaki-Tanaka R; Nagulapalli Venkata KC; Okamoto H; Moriyama M; Kanda T
Int J Mol Sci; 2022 May; 23(11):. PubMed ID: 35682728
[TBL] [Abstract][Full Text] [Related]
14. Favipiravir Inhibits Hepatitis A Virus Infection in Human Hepatocytes.
Sasaki-Tanaka R; Shibata T; Okamoto H; Moriyama M; Kanda T
Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269774
[TBL] [Abstract][Full Text] [Related]
15. Suppression of La antigen exerts potential antiviral effects against hepatitis A virus.
Jiang X; Kanda T; Wu S; Nakamoto S; Saito K; Shirasawa H; Kiyohara T; Ishii K; Wakita T; Okamoto H; Yokosuka O
PLoS One; 2014; 9(7):e101993. PubMed ID: 24999657
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory effects on HAV IRES-mediated translation and replication by a combination of amantadine and interferon-alpha.
Yang L; Kiyohara T; Kanda T; Imazeki F; Fujiwara K; Gauss-Müller V; Ishii K; Wakita T; Yokosuka O
Virol J; 2010 Sep; 7():212. PubMed ID: 20815893
[TBL] [Abstract][Full Text] [Related]
17. Incidence of HAV and HBV infections and vaccination rates in patients with autoimmune liver diseases.
Wörns MA; Teufel A; Kanzler S; Shrestha A; Victor A; Otto G; Lohse AW; Galle PR; Höhler T
Am J Gastroenterol; 2008 Jan; 103(1):138-46. PubMed ID: 17970833
[TBL] [Abstract][Full Text] [Related]
18. The sirtuin inhibitor sirtinol inhibits hepatitis A virus (HAV) replication by inhibiting HAV internal ribosomal entry site activity.
Kanda T; Sasaki R; Nakamoto S; Haga Y; Nakamura M; Shirasawa H; Okamoto H; Yokosuka O
Biochem Biophys Res Commun; 2015 Oct; 466(3):567-71. PubMed ID: 26388050
[TBL] [Abstract][Full Text] [Related]
19. Novel flavonoid hybrids as potent antiviral agents against hepatitis A: Design, synthesis and biological evaluation.
Shi S; Zheng X; Suzuki R; Li Z; Shiota T; Wang J; Hirai-Yuki A; Liu Q; Muramatsu M; Song SJ
Eur J Med Chem; 2022 Aug; 238():114452. PubMed ID: 35597006
[TBL] [Abstract][Full Text] [Related]
20. T cells protect against hepatitis A virus infection and limit infection-induced liver injury.
Misumi I; Mitchell JE; Lund MM; Cullen JM; Lemon SM; Whitmire JK
J Hepatol; 2021 Dec; 75(6):1323-1334. PubMed ID: 34331968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
